Search for: "MYLAN PHARMACEUTICALS INC"
Results 141 - 160
of 497
Sort by Relevance
|
Sort by Date
8 Feb 2017, 3:09 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
31 Jan 2017, 8:55 pm
§ 102(f), in Cumberland Pharmaceuticals Inc. v. [read post]
16 Jan 2017, 5:44 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
21 Dec 2016, 7:18 am
Mylan Pharmaceutical Inc. says they expect PTAB decisions on the IPRs sometime during the fourth quarter of 2017. [read post]
7 Dec 2016, 9:59 pm
Mylan Pharmaceuticals Inc. v. [read post]
14 Nov 2016, 2:01 pm
As previously reported, Mylan Inc., the pharmaceutical manufacturer of the life-saving EpiPen, misclassified their brand name drug as generic for years, thus deceiving and effectively defrauding governmentally-funded insurance providers Medicare and Medicaid, resulting in millions of dollars in overpayments by taxpayers, all in an effort to save themselves money prior to hiking the price of The post EpiFail: Gov’t Knew EpiPen Was Misclassified in 2009 appeared first… [read post]
14 Nov 2016, 9:16 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
18 Oct 2016, 8:23 pm
The petition of the day is: Mylan Pharmaceuticals Inc. v. [read post]
13 Oct 2016, 6:50 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
28 Sep 2016, 8:39 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Mylan Pharmaceuticals, et al. v. [read post]
15 Sep 2016, 4:00 am
Mylan Pharmaceuticals ULC, 2015 FC 125 at paragraph 154, to assist with determining whether a feature was an instruction on how to administer a dosage or an aspect of the dosage form itself for determining whether a claim was patentable subject matter or a method medical treatment. [read post]
9 Sep 2016, 4:15 am
The IPRs, which were filed by American pharmaceutical developer Mylan Inc. [read post]
6 Sep 2016, 3:36 pm
The New York Attorney General is investigating whether leading EpiPen Manufacturer, Mylan Pharmaceuticals, violated New York antitrust laws by inserting anticompetitive terms into its EpiPen sales contracts with numerous local school systems. [read post]
2 Sep 2016, 2:15 am
Mylan Pharmaceuticals, Inc., 817 F.3d 755 (Fed. [read post]
28 Jun 2016, 6:41 am
Momenta Pharmaceuticals, Inc., et al., No. 15-1402 (scope of 271(e) safe harbor) Exhaustion: Impression Products, Inc. v. [read post]
3 Jun 2016, 6:40 am
Momenta Pharmaceuticals, Inc., et al., No. 15-1402 (scope of 271(e) safe harbor) Exhaustion: Impression Products, Inc. v. [read post]
18 May 2016, 8:19 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
3 May 2016, 9:00 pm
Guest Post By: Paul Dietze and Mini Kapoor, Haynes and Boone, LLP[1] On March 18, 2016, the Federal Circuit held that Mylan Pharmaceuticals, Inc. [read post]
3 May 2016, 1:42 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
2 May 2016, 6:17 am
The Federal Circuit held that Mylan Pharmaceuticals, Inc. [read post]
